Abstract
6045 Background: El Álamo project is a retrospective analysis of 15381 patients (pts) diagnosed of breast cancer (BC) across 43 of the main Spanish hospitals. Methods: Two cohorts were analysed: Álamo I (AI) consisted of 4532 pts diagnosed with BC between 1990 and 1993; Álamo II (AII) consisted of 10849 pts diagnosed between 1994 and 1999. AI and AII data were collected by end of year (yr) 2000 and 2003, respectively. 158 items per pt were recorded, including demographic, therapeutic and outcome data. Pts with operable, node-positive (NP) disease were selected. Results: In AI project, 51% of all pts presented with NP disease, vs. 45% in AII. Median age at diagnosis was 56 yr (AI) vs. 57 yr (AII); 63.1% vs. 63.5% of pts were postmenopausal. Percentage of pts with 1–3 NP increased from 52.2% (AI) to 54.5% (AII); whereas it decreased for pts with 4–9 NP (30% in AI vs. 26.7% in AII); proportion of pts with 3 10 NP was similar in both groups (15.5% in AI vs. 15.7% in AII). Regarding treatment, 99% of pts in both AI and AII received adjuvant therapy (AT). AT in AI group were: chemotherapy (CT) (70.4%), hormone therapy (HT) (60.6%) and radiotherapy (RT) (44.7%), usually in combination. AT in AII group were: CT (82.2%), HT (75.5%) and RT (59.2%), usually in combination. 30 pts (2.2%) were treated with high dose CT in AI vs. 296 pts (9.1%) in AII. 51.3% of all pts in AI received an anthracycline containing regimen as CT vs. 61.6% in AII. BC recurrence rate has diminished from 46.4% (AI) to 29.6% (AII). The respective nine-year survival rates for AI and AII were 58.9% (CI95%; 56.3%–61.4%) and 68.1% (CI95%; 65.5%–70.7%).Conclusions: The relative population of operable, NP BC pts has decreased by 6% in Spain between 1990 and 1997. This seems to be the main cause of outcome improvement in this group of pts, although a contribution of therapy cannot be ruled out. No significant financial relationships to disclose.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
